← Back to Search

Information Sharing for Chronic Kidney Disease

N/A

Recruiting

Led By Navdeep Tangri, MD PhD FRCPC

Research Sponsored by University of Manitoba

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

All patients with CKD Stages G3-G5 who attend the 32 clinics.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months after intervention

Awards & highlights

Study Summary

This trial will test whether providing patients with information about their risk of kidney failure improves quality of care, health literacy, and trust in the care they are receiving.

Who is the study for?

This trial is for adults with moderate to severe chronic kidney disease (CKD Stages G3-G5) who are treated at primary care clinics in Manitoba and Alberta that use an electronic medical record system capable of integrating the kidney failure risk equation (KFRE).Check my eligibility

What is being tested?

The study tests if providing personalized information about kidney failure risk, alongside usual care, improves patient care. Clinics will either integrate this approach or continue with standard care without personalized risk info.See study design

What are the potential side effects?

Since this intervention involves knowledge translation rather than medication, traditional side effects aren't expected. However, there may be impacts on patients' emotional well-being due to awareness of their CKD progression risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have chronic kidney disease between stages 3 to 5.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months after intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months after intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months after intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of CKD patients in each clinic who have albuminuria (albumin-creatinine ratio (ACR)) tested

The percentage of patients who are appropriately managed with an ACEi or ARB, and who either have CKD and diabetes, or who have CKD and a urine ACR >30 mg/mmol.

Secondary outcome measures

Appropriate medication usage

Appropriate referral for patients at high risk for kidney failure

Clinical provider's satisfaction with the risk prediction tools and clinical decision aids.

+7 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Active Knowledge Translation GroupExperimental Treatment1 Intervention

Primary care clinics receiving the active knowledge translation intervention.

Group II: Control GroupActive Control1 Intervention

Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Canadian Primary Care Sentinel Surveillance NetworkUNKNOWN

University of ManitobaLead Sponsor

595 Previous Clinical Trials

193,222 Total Patients Enrolled

Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney DiseaseOTHER

1 Previous Clinical Trials

2,500 Total Patients Enrolled

Media Library

Active Knowledge Translation Clinical Trial Eligibility Overview. Trial Name: NCT03365063 — N/A

Chronic Kidney Disease Research Study Groups: Active Knowledge Translation Group, Control Group

Chronic Kidney Disease Clinical Trial 2023: Active Knowledge Translation Highlights & Side Effects. Trial Name: NCT03365063 — N/A

Active Knowledge Translation 2023 Treatment Timeline for Medical Study. Trial Name: NCT03365063 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings for individuals to join this experiment?

"The clinical trial is actively seeking volunteers; the initial posting was made on August 24th 2018, with a recent update seen on June 9th 2022."

Answered by AI

What is the scope of enrollees for this experiment?

"Affirmative. According to clinicaltrials.gov, this trial is recruiting and was posted on August 24th 2018 with the latest edit occuring June 9th 2022. Approximately 6300 participants are sought from two separate medical facilities."

Answered by AI

What objectives is this experiment seeking to accomplish?

"The principal outcome of this trial, to be evaluated within a year after the intervention, is the proportion of patients who are being treated adequately with ACEi or ARB and have either CKD and diabetes, or CKD plus urine ACR >30 mg/mmol. Subsidiary objectives include assessing clinical providers' satisfaction with risk prediction tools & decision aids (measured by Likert scale points), monitoring cardiovascular risk factors for CKD patients (proportion w/ statin prescription in EMR) & evaluating patient's kidney-related health literacy (number of KiKS survey answers)."

Answered by AI

Recent research and studies

Canadian Journal of Kidney Health and DiseaseJournal

Integrating Risk-based Care for Patients with Chronic Kidney Disease in the Community: Study Protocol for a Cluster Randomized Trial

Harasemiw, Oksana, Neil Drummond, Alexander Singer, Aminu Bello, Paul Komenda, Claudio Rigatto, Jordyn Lerner, Dwight Sparkes, Thomas W. Ferguson, and Navdeep Tangri. 2019. “Integrating Risk-based Care for Patients with Chronic Kidney Disease in the Community: Study Protocol for a Cluster Randomized Trial”. Canadian Journal of Kidney Health and Disease. SAGE Publications. doi:10.1177/2054358119841611.

Kidney International ReportsJournal

Prevalence and Demographics of CKD in Canadian Primary Care Practices: A Cross-sectional Study

Bello, Aminu K., Paul E. Ronksley, Navdeep Tangri, Julia Kurzawa, Mohamed A. Osman, Alexander Singer, Allan Grill, et al.. 2019. “Prevalence and Demographics of CKD in Canadian Primary Care Practices: A Cross-sectional Study”. Kidney International Reports. Elsevier BV. doi:10.1016/j.ekir.2019.01.005.

JAMA Network OpenJournal

Quality of Chronic Kidney Disease Management in Canadian Primary Care

Bello, Aminu K., Paul E. Ronksley, Navdeep Tangri, Julia Kurzawa, Mohamed A. Osman, Alexander Singer, Allan K. Grill, et al.. 2019. “Quality of Chronic Kidney Disease Management in Canadian Primary Care”. JAMA Network Open. American Medical Association (AMA). doi:10.1001/jamanetworkopen.2019.10704.

clinicaltrials.govStudy